Reviva Pharmaceuticals Holdings, Inc. (RVPH)Healthcare | Biotechnology | Cupertino, United States | OTC Markets OTCQB
0.52 USD
+0.01
(2.775%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Aug. 22, 2026, 4:55 a.m. EDT
This biotech stock is in a terminal phase of delisting and insolvency. The company has filed to remove its ticker from Nasdaq, trading now on the OTC market, which signals a severe loss of institutional credibility and liquidity. Fundamentally, the business is bleeding cash with negative free cash flow and a negative return on equity, while analysts have issued a uniform 'strong buy' recommendation based solely on a theoretical 1-for-20 reverse split—a maneuver designed to prop up the share price artificially rather than reflect real value creation. The price action confirms this distress, having collapsed from a high of $17.20 to under $0.50, a decline of over 97%. With no dividend to speak of and a balance sheet that cannot sustain operations without external capital, the long-term outlook is bleak. Short-term, the technical setup is broken, and the options market is pricing in a further collapse, making this a dangerous speculative vehicle with no margin of safety. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.117120 |
| AutoARIMA | 0.186497 |
| AutoETS | 0.196116 |
| MSTL | 0.205716 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 2.42 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.399 |
| Excess Kurtosis | -0.82 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.948 |
| Market Cap | 6,797,730 |
| Forward P/E | -0.61 |
| Beta | 0.49 |
| Website | https://www.revivapharma.com |
As of Aug. 22, 2026, 4:55 a.m. EDT: Speculators are positioning for a significant downside move, evidenced by heavy open interest in deep out-of-the-money puts (strike $2.00) compared to virtually no put volume at lower strikes. Conversely, call activity is concentrated in the money, suggesting a 'long gamma' or hedging strategy rather than a bullish bet on further appreciation. The massive disparity in implied volatility between calls (56%) and puts (347%) indicates the market prices in a catastrophic drop scenario while remaining indifferent to upside moves.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.94394445 |
| Address1 | 10,080 N. Wolfe Road |
| Address2 | Suite SW3-200 |
| All Time High | 192.2 |
| All Time Low | 0.262 |
| Ask | 0.52 |
| Ask Size | 7,173 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 30,659 |
| Average Daily Volume3 Month | 65,766 |
| Average Volume | 65,766 |
| Average Volume10Days | 30,659 |
| Beta | 0.489 |
| Bid | 0.515 |
| Bid Size | 13,326 |
| Book Value | 1.361 |
| City | Cupertino |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.5185 |
| Current Ratio | 3.563 |
| Custom Price Alert Confidence | LOW |
| Date Short Interest | 1,777,507,200 |
| Day High | 0.5198 |
| Day Low | 0.5 |
| Debt To Equity | 0.948 |
| Display Name | Reviva Pharmaceuticals |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda Margins | 0.0 |
| Enterprise Value | -13,131,682 |
| Eps Current Year | -0.85 |
| Eps Forward | -0.85 |
| Eps Trailing Twelve Months | -1.03 |
| Esg Populated | 0 |
| Exchange | OQB |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 408 904 6270 |
| Fifty Day Average | 0.5312672 |
| Fifty Day Average Change | -0.012767255 |
| Fifty Day Average Change Percent | -0.0240317 |
| Fifty Two Week Change Percent | -94.39445 |
| Fifty Two Week High | 17.2 |
| Fifty Two Week High Change | -16.681501 |
| Fifty Two Week High Change Percent | -0.9698547 |
| Fifty Two Week Low | 0.262 |
| Fifty Two Week Low Change | 0.25649998 |
| Fifty Two Week Low Change Percent | 0.97900754 |
| Fifty Two Week Range | 0.262 - 17.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,608,042,600,000 |
| Float Shares | 11,861,876 |
| Forward Eps | -0.85 |
| Forward P E | -0.60999995 |
| Free Cashflow | -13,689,651 |
| Full Exchange Name | OTC Markets OTCQB |
| Full Time Employees | 14 |
| Fullday Price | 0.5185 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 0 |
| Held Percent Insiders | 0.07727 |
| Held Percent Institutions | 0.08241 |
| Implied Shares Outstanding | 13,110,377 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,773,014,400 |
| Last Split Factor | 1:20 |
| Long Business Summary | Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California. |
| Long Name | Reviva Pharmaceuticals Holdings, Inc. |
| Market | us_market |
| Market Cap | 6,797,730 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_126911636 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -13,022,270 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,614,185 |
| Number Of Analyst Opinions | 2 |
| Open | 0.5 |
| Operating Cashflow | -17,304,396 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 408 501 8881 |
| Previous Close | 0.5045 |
| Price Eps Current Year | -0.60999995 |
| Price Hint | 4 |
| Price To Book | 0.38096988 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.352 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.013999999 |
| Regular Market Change Percent | 2.7750247 |
| Regular Market Day High | 0.5198 |
| Regular Market Day Low | 0.5 |
| Regular Market Day Range | 0.5 - 0.5198 |
| Regular Market Open | 0.5 |
| Regular Market Previous Close | 0.5045 |
| Regular Market Price | 0.5185 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 5,725 |
| Return On Assets | -0.51404 |
| Return On Equity | -1.76596 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 13,110,377 |
| Shares Percent Shares Out | 0.1457 |
| Shares Short | 1,866,151 |
| Shares Short Previous Month Date | 1,774,915,200 |
| Shares Short Prior Month | 1,834,224 |
| Short Name | Reviva Pharmaceuticals Holdings |
| Short Percent Of Float | 0.1495 |
| Short Ratio | 3.35 |
| Source Interval | 15 |
| State | CA |
| Symbol | RVPH |
| Target High Price | 30.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 17.5 |
| Target Median Price | 17.5 |
| Total Cash | 19,889,960 |
| Total Cash Per Share | 1.517 |
| Total Debt | 144,093 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.03 |
| Trailing Peg Ratio | None |
| Triggerable | 0 |
| Two Hundred Day Average | 3.3293805 |
| Two Hundred Day Average Change | -2.8108807 |
| Two Hundred Day Average Change Percent | -0.84426534 |
| Type Disp | Equity |
| Volume | 5,725 |
| Website | https://www.revivapharma.com |
| Zip | 95,014 |